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ABSTRACT
Background Interferon γ (IFNγ) is considered a
seminal cytokine in the pathogenesis of giant cell
arteritis (GCA), but its functional role has not been
investigated. We explored changes in inﬁltrating cells
and biomarkers elicited by blocking IFNγ with a
neutralising monoclonal antibody, A6, in temporal
arteries from patients with GCA.
Methods Temporal arteries from 34 patients with GCA
(positive histology) and 21 controls were cultured on 3D
matrix (Matrigel) and exposed to A6 or recombinant
IFNγ. Changes in gene/protein expression were
measured by qRT-PCR/western blot or immunoassay.
Changes in inﬁltrating cells were assessed by
immunohistochemistry/immunoﬂuorescence. Chemotaxis/
adhesion assays were performed with temporal artery-
derived vascular smooth muscle cells (VSMCs) and
peripheral blood mononuclear cells (PBMCs).
Results Blocking endogenous IFNγ with A6 abrogated
STAT-1 phosphorylation in cultured GCA arteries.
Furthermore, selective reduction in CXCL9, CXCL10 and
CXCL11 chemokine expression was observed along with
reduction in inﬁltrating CD68 macrophages. Adding IFNγ
elicited consistent opposite effects. IFNγ induced CXCL9,
CXCL10, CXCL11, CCL2 and intracellular adhesion
molecule-1 expression by cultured VSMC, resulting in
increased PBMC chemotaxis/adhesion. Spontaneous
expression of chemokines was higher in VSMC isolated
from GCA-involved arteries than in those obtained from
controls. Incubation of IFNγ-treated control arteries with
PBMC resulted in adhesion/inﬁltration by CD68
macrophages, which did not occur in untreated arteries.
Conclusions Our ex vivo system suggests that IFNγ
may play an important role in the recruitment of
macrophages in GCA by inducing production of speciﬁc
chemokines and adhesion molecules. Vascular wall
components (ie, VSMC) are mediators of these functions
and may facilitate progression of inﬂammatory inﬁltrates
through the vessel wall.
INTRODUCTION
Giant cell arteritis (GCA) is a chronic inﬂammatory
disease targeting large and medium-sized arteries in
aged individuals.1 In spite of the initial response to
high-dose glucocorticoids (GCs), 40–60% of
patients relapse when GCs are tapered and pro-
longed GC treatment results in signiﬁcant side
effects.2
Search for new therapeutic options requires
better understanding of pathogenesis. GCA has
been classically considered a Th1-mediated disease
based on the granulomatous nature of inﬂamma-
tory lesions with the presence of giant cells.1 3
Moreover, while transcripts of several cytokines (ie,
interleukin (IL)-6, tumour necrosis factor-α (TNFα)
can be detected in unaffected temporal artery biop-
sies (TABs),4–7 IFNγ, the distinctive cytokine pro-
duced by Th1 lymphocytes, is selectively expressed
in GCA lesions.4 7–12 Recently, Th17-mediated
mechanisms are also emerging as a relevant compo-
nent of GCA pathogenesis.9–13
IFNγ has important roles in innate and adaptive
immunity. It is primarily expressed by Th1 and
natural killer (NK) cells and also by plasmacytoid
dendritic cells, B cells and macrophages.14 15 IFNγ
signals by inducing dimerisation of its receptor
chains, which, in turn, induces phosphorylation of
JAK 1 and JAK 2, creating binding sites for
STAT-1.14 16 17 STAT-1 phosphorylation results in
STAT-1 dimerisation or formation of multimolecu-
lar complexes (ie, ISFG3 composed by STAT-1,
STAT-2 and IRF9 molecules) subsequently inducing
transcription of genes bearing gamma-activated
sequences or interferon-stimulated responsive ele-
ments (ISREs), respectively, in their promoter
regions.14 16 17 Some of the STAT-1-induced target
genes are themselves transcription factors (ie,
IRFs), creating subsequent waves of inﬂammatory
molecule expression.18 Adding complexity, IFNγ
may also induce STAT-3, particularly in conditions
of STAT-1 paucity.19 IFNγ promotes NK cell activ-
ity, macrophage activation, Th1 differentiation and
expression of class I and class II major histocom-
patibility complex molecules on antigen-presenting
cells.14–21 Based on these functions, IFNγ is
thought to have a major role in GCA. Its expression
by adventitial inﬁltrates in early GCA lesions sug-
gests a relevant role from the initial steps of vascu-
lar inﬂammation.11 22
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To date, no mechanistic studies assessing the role of IFNγ in
the development of full-blown lesions in GCA have been per-
formed. In this study, we explored functional roles of IFNγ on
GCA lesions by exposing cultured temporal artery sections from
patients with GCA to a neutralising anti-human IFNγ monoclo-
nal antibody.
PATIENTS AND METHODS
Patient samples
TABs were performed to 55 patients with suspected GCA for
diagnostic purposes. A 5–15 mm segment was saved for the
present study. Thirty-four patients had histopathological features
of GCA in their TAB. Thirteen of them had started GC treat-
ment 3.6±3.2 days before TAB. Twenty-one patients had no
inﬂammatory inﬁltrates and served as controls. Clinical data of
GCA patients and ﬁnal diagnosis in control patients are dis-
closed in online supplementary tables S1 and S2, respectively.
Neutralising, monoclonal antibody A6 against IFNγ
A6 is a fully human monoclonal antibody generated in the
laboratories of Novimmune (Geneva, Switzerland) from human
immunoglobulin libraries using in vitro display technologies.
A6 binds to human IFNγ and neutralises its bioactivity.
Temporal artery culture
Temporal artery sections from patients with GCA and controls
were embedded in Matrigel to ensure prolonged survival, cul-
tured ex vivo as described7 with or without A6 antibody (10 μg/
mL), recombinant IFNγ at 100 ng/mL (R&D Systems,
Minneapolis, Minnesota, USA), human non-immune immuno-
globulin IgG1 at 10 μg/mL (Sigma, Ayrshire, UK) as a negative
control or dexamethasone (0.5 μg/mL, Sigma). Each condition
was tested in 3–4 replicate wells. Biopsies were frozen in TRIzol
reagent (Life Technologies) for RNA extraction or in radioim-
munoprecipitation assay buffer with protease and phosphatase
inhibitors for western blot studies.
Cell culture
Vascular smooth muscle cells (VSMCs) were isolated from TABs
as previously described22 and used after 3–8 doubling passages.
Peripheral blood mononuclear cells (PBMCs) were obtained
from whole blood of healthy donors using Lymphoprep
(Axis-Shield, Oslo, Norway) (see culture details in online sup-
plementary methods).
In speciﬁc experiments, VSMCs were seeded in 12-well plates
and cultured alone or with 0.5×106 PBMC/well. At the end of
the co-culture period, PBMCs were isolated from supernatants
by centrifugation. The underlying VSMCs were separately
recovered after gentle treatment with EDTA (Versene, Life
Technologies) to remove adherent PBMC.
Gene expression analysis
Total RNA was obtained from cultured arteries or cells and
cDNA was obtained by reverse-transcription (see online supple-
mentary methods). Speciﬁc pre-developed TaqMan probes from
Applied Biosystems (TaqMan Gene Expression Assays) (see
online supplementary table S3) were used for PCR ampliﬁca-
tion. Fluorescence was detected with ABI PRISM 7900
Hardware and results were analysed with the Sequence
Detection Software V.2.3 (Applied Biosystems). Gene expression
was normalised to the expression of the endogenous control
GUSb using comparative ΔCt method.5–7 11 mRNA concentra-
tion was expressed in relative units with respect to GUSb
expression.
Chemokine secretion
CXCL9, CXCL10 and CXCL11 concentrations in supernatants
were measured by immunoassay using Quantikine (R&D
Systems).
STAT-1 and STAT-3 phosphorylation in cultured arteries
Lysates were obtained from cultured artery sections or VSMC
and phospho-STAT-1/total STAT-1 and phosho-STAT-3/total
STAT-3 were assessed by western blot (see online supplementary
methods).
Immunohistochemistry and immunoﬂuorescence staining
Detailed immunostaining of cultured temporal artery sections or
VSMC, as well as primary and secondary antibodies used, are
depicted in online supplementary methods.
Chemotaxis assay
PBMC chemotaxis was assessed using Boyden chambers with
5 μm pore polycarbonate ﬁlters (see speciﬁc details in online
supplementary methods).
Cell adhesion assays
VSMCs were grown to conﬂuence in 96-well plates and stimu-
lated with recombinant IFNγ. After 24 h 7.5×104 PBMCs per
well were added and incubated at 37°C for 30 min. Wells were
gently rinsed with phosphate-buffered saline and cells were
ﬁxed and stained with 0.2% crystal violet in 20% methanol for
10 min. Plates were extensively washed and crystal violet was
solubilised with 1% sodium dodecyl sulfate (50 μL/well).
Optical density was assessed by spectrophotometry at 560 nm
wavelength.
Statistical analysis
Student’s t test, when applicable, or Mann–Whitney test was
applied for independent or paired samples for statistical analysis
using SPSS software, PASW V.18.0.
RESULTS
Clone A6, a neutralising human monoclonal antibody
against IFNγ, recognises IFNγ in GCA lesions and interferes
with IFNγ-mediated signalling
Since A6 was screened and selected by its potential to neutralise
IFNγ in vitro, we assessed its ability to bind IFNγ expressed in
GCA lesions. As shown in ﬁgure 1, biotinylated A6 antibody
immunostained GCA-involved temporal artery sections, whereas
immunostaining with biotinylated human IgG1 was negative.
Moreover, immunostaining of non-inﬂamed temporal artery sec-
tions from a control individual was negative according to the
absence of IFNγ expression in normal arteries.4 7
Temporal artery culture in 3-D matrix has been shown to be a
suitable model to test the effects of easily diffusing molecules
such as dexamethasone.7 However, it is not known whether
complex molecules such as monoclonal antibodies are able to
elicit biological responses in this system. To test this point, we
investigated whether A6 was able to interfere with
IFNγ-mediated signalling in cultured arteries by exploring the
phosphorylation status of the transcription factors STAT-1 and
STAT-3. As shown in ﬁgure 1E, F, normal arteries in culture had
a remarkable constitutive expression and phosphorylation of
STAT-3 but not STAT-1. Involved GCA arteries in culture had
increased expression and phosphorylation of STAT-1 and
decreased expression and phosphorylation of STAT-3 compared
with cultured normal arteries. A6 antibody decreased expression
and phosphorylation of STAT-1, whereas STAT-3 expression/
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phosphorylation was not substantially affected. Treatment with
recombinant IFNγ strongly increased expression and phosphor-
ylation of STAT-1.
Neutralising endogenous IFNγ production selectively
downregulates CXCL9, CXCL10, CXCL11 chemokines and
STAT-1 expression in cultured GCA arteries: adding
exogenous IFNγ elicits opposite effects
We investigated the effects of neutralising IFNγ with A6 on the
expression of a variety of candidate molecules relevant to the
pathogenesis of vascular inﬂammation and remodelling in
GCA.3 5 11 22–30 Molecules investigated included transcription
factors involved in T-cell functional differentiation, proinﬂam-
matory cytokines, chemokines/chemokine receptors, adhesion
molecules, growth factors, metalloproteinases and their
natural inhibitors, and extracellular matrix proteins (table 1 and
ﬁgure 2). Since the temporal artery culture conveys by itself a
downregulation of IFNγ expression with respect to the original
fresh arteries, which may have minimised these results,7 we
sought to conﬁrm the potential effects of IFNγ revealed by
inhibition with A6 antibody by treating cultured GCA arteries
with recombinant IFNγ.
Among the molecules tested, neutralising endogenous IFNγ
with A6 mainly downregulated STAT-1 and chemokine CXCL9,
CXCL10 and CXCL11 mRNAs (ﬁgure 2A). As shown in ﬁgure
2B, exposure of cultured GCA arteries to IFNγ elicited the
expected opposite effects and induced strong expression of
STAT-1 and chemokines CXCL9, CXCL10 and CXCL11
(ﬁgure 2B). CXCL9 and CXCL10 concentrations in the super-
natant ﬂuid were also reduced upon A6 antibody treatment and
increased under exposure to recombinant IFNγ (ﬁgure 2C).
Concentrations of CXCL11 were around the detection level and
were not substantially modiﬁed by A6 antibody or recombinant
IFNγ, suggesting that CXCL11 is not secreted or is retained in
the extracellular matrix.
Table 1 shows the effect of blocking IFNγ with A6, as well as
the effect of adding recombinant IFNγ on the additional mole-
cules tested. Neutralising IFNγ with A6 tended to decrease
HLA-DRA, TBX21, NOS-2, TNFα, IL-6, CCL2, CXCR3, intra-
cellular adhesion molecule-1 (ICAM-1) and platelet-derived
growth factor A mRNAs and, consistently, these tended to
increase upon exposure to recombinant IFNγ. However, with the
exception of TNFα, differences were not statistically signiﬁcant,
possibly due to the relatively low number of specimens analysed
and the wide individual variability in expression of inﬂammatory
products. Dexamethasone was able to markedly downregulate
additional relevant molecules not inﬂuenced by A6 (table 1).
VSMCs contribute to chemokine production induced by IFNγ
Most of the effects of IFNγ have been investigated in T cells,
monocytes and endothelial cells. To mimic vascular inﬂamma-
tory inﬁltrates, we co-cultured PBMC from healthy donors with
human temporal artery-derived VSMC, the main component of
the arterial wall. Co-culture induced a variety of chemokines
Figure 1 Interferon γ (IFNγ) expression in arteries with giant cell arteritis (GCA) and the effects of IFNγ on cultured temporal arteries from
patients with GCA. (A–D) Immunostaining with A6 or control IgG1 on normal temporal arteries or GCA-involved arteries. (A) Histologically negative
temporal artery from a control individual incubated with biotinylated A6 (negative control). (B) GCA-involved artery incubated with biotinylated A6
antibody (brown staining reﬂects IFNγ expression). (C) A GCA-involved artery incubated with biotinylated non-immune human IgG1 (isotype control).
(D) A GCA-involved artery incubated with the detection system reagents but no A6 (negative control). (E) Western blot performed to assess
phosphorylated or total STAT-1 and STAT-3 in protein extracts of a cultured histologically negative biopsy (Neg Bx) and a cultured GCA-involved
biopsy (GCA) untreated (Ø), exposed to A6 (10 μg/mL), IFNγ (100 ng/mL), human IgG1 (IgG; 10 μg/mL) or dexamethasone (Dexa; 0.5 μg/mL) for
5 days. The experiment was repeated twice with consistent results and a representative blot is shown. β-Actin was used as a control for loading.
(F) Densitometric analysis of bands obtained in western blot experiments is exempliﬁed in (E).
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not only in PBMC but also in VSMC, indicating that VSMCs
are an active source of chemokines in an inﬂammatory micro-
environment (ﬁgure 3A). IFNγ was produced and secreted by
PBMC, basally and in co-culture (see online supplementary
ﬁgure S1). In accordance with the previous results, neutralising
IFNγ with A6 strongly and selectively inhibited CXCL9,
CXCL10 and CXCL11 chemokine expression by all cell types
(ﬁgure 3A). A slight, non-signiﬁcant, reduction in STAT-1 and
adhesion molecule ICAM-1 was observed. No effects of A6
were observed on the expression of STAT-3, VCAM-1 or other
chemokines tested in this multicellular system (ﬁgure 3A and
online supplementary ﬁgure S2).
To conﬁrm that VSMC are an important source of chemo-
kines upon IFNγ inﬂuence, we exposed human temporal artery-
derived VSMC to IFNγ, which elicited a remarkable increase in
STAT-1 (ﬁgure 3B). An induction of CXCL9, CXCL10 and
CXCL11 and upregulation of constitutive CCL2 was obtained,
whereas expression of other chemokines related to Th1
responses (ie, CCL3, CCL4 or CCL5) or CXCL8 was not sig-
niﬁcantly induced (ﬁgure 3B). Promoter analysis (4 kb upstream
and 1 kb downstream of the transcription initiating sequence) of
chemokine genes was performed using Chip Bioinformatics
Mapper (http://snpper.chip.org/mapper/mapper-main).31 The
promoters of CXCL9, 10, and 11 as well as CCL2 shared ISRE
sequences, whereas the remaining chemokines tested did not,
supporting the exquisite sensitivity of these cytokines to IFNγ
exposure. However, although IFNγ signiﬁcantly upregulated
constitutive CCL2 expression by cultured VSMC, A6 failed to
downregulate CCL2 in multicellular systems such as PBMC/
VSMC co-culture or whole GCA arteries where other inducers
may be present (table 1 and ﬁgure 3A).
As previously demonstrated in other settings,18 32 33 IFNγ
also upregulated STAT-1 and adhesion molecule ICAM-1
expression by cultured VSMC and induced a slight expression
of VCAM-1 and STAT-3 (ﬁgure 3B).
We next cultured temporal artery-derived VSMC from 8
patients and 11 controls and investigated chemokine production
at passage zero to avoid phenotypic changes induced by pro-
longed culture. As shown in ﬁgure 3C, patient-derived VSMC
conserved IFNγ signature and expressed signiﬁcantly higher
mRNA concentrations of IFNγ-induced chemokine CXCL9 and
a tendency to increased expression of CXCL10 and CCL2 than
VSMC derived from control individuals. Higher mRNA concen-
trations of other chemokines not clearly inﬂuenced by IFNγ in
our experiments, particularly CCL4, were also observed. This
may indicate VSMC exposure to stimuli other than IFNγ or to
second-wave IFNγ-induced mediators in the complex multicellu-
lar and multimolecular microenvironment existing in GCA
lesions.
Functional relevance of chemokine and adhesion molecule
expression by VSMC
Treatment of cultured temporal artery-derived VSMC with
IFNγ resulted in an increase in adhesion to PBMC (ﬁgure 4A).
The effect of IFNγ on ICAM-1 expression by VSMC was con-
ﬁrmed in GCA lesions. VSMC expressed ICAM-1 in cultured
GCA arteries, particularly in the vicinity of inﬂammatory inﬁl-
trates. ICAM-1 expression was reduced in sections treated with
A6 antibody and increased in sections treated with IFNγ
(ﬁgure 4B). As already described,25 ICAM-1 expression was also
observed in vasa vasorum endothelial cells and inﬂammatory
cells (ﬁgure 4B).
Table 1 Mean fold change in mRNA of selected representative
genes related to T helper functional differentiation, inflammation and
vascular remodelling in cultured temporal arteries from 34 patients
with GCA and 21 controls subjected to different treatments (control
IgG1, A6, recombinant IFNγ or dexamethasone)
GCA/control GCA biopsies
Fold increase Clone A6/IgG1 IFNγ/untreated
Dexa/
untreated
Transcription factors
TBX21 3.1154* 0.7133 2.7776* 0.9522
GATA3 1.7611* 1.1780 1.3536 0.7716
RORC 3.6482* 0.8558 1.3571 0.8380*
STAT-3 0.5913 0.9232 1.6143 1.0565
Proinflammatory molecules
Cytokines
IL-1β 3.6162* 0.9041 1.1481 0.0342
TNFα 1.6621* 0.7561* 2.7333* 0.3047*
IL-6 1.4685 0.7026 1.5621 0.0757*
IFNγ 15.0840* 0.9119 0.6848 0.3869*
IL17A 103.5418* 1.4793 0.5557 0.0279*
Chemokines
CCL2 1.6839 0.8950 1.2292 0.3424*
CCL3 6.3415* 0.9815 0.4381 0.2125*
CCL4 13.9455* 1.0598 0.1611 0.2058
CCL5 4.8446* 1.2153 1.3709 0.6600
CXCL8 1.3023 0.9805 0.9512 0.0748*
Chemokine receptors
CCR2 6.9054* 1.3463 2.6116 0.5746
CXCR3 10.0717* 0.6640 2.1125* Not
done
Adhesion molecules
ICAM-1 1.7275 0.8225 2.0204 0.1137
VCAM-1 0.7031 0.9611 1.6861 0.0787
Other
HLADRA 3.8304* 0.7373 3.0312* 0.8810
NOS-2 1.7010 0.2443 2.7067 1.7251
Vascular remodelling-related molecules
Growth factors
PDGFA 0.4752* 0.7690 1.6640 0.4331
PDGFB 0.6820 0.8081 1.0921 0.6338
TGFβ 0.6106* 1.0119 1.2298 0.5117
Extracellular matrix proteins
FN1 0.8757 1.0473 Not done 2.3182
COL1 1.9086 0.9953 Not done 0.9594
COL3 0.9037 0.8602 Not done 1.0790
Metalloproteases
MMP-2 0.5738* 0.9101 0.5082 0.5827
MMP-9 2.3692* 0.8468 0.8204 0.0708*
MMP inhibitors
TIMP1 1.8323* 0.9844 1.0956 0.3405*
TIMP2 0.5663* 0.9815 0.9614 0.7737
Number of specimens analysed: negative biopsies: 21; untreated GCA: 29; GCA treated
with A6: 21; GCA treated with IgG1: 18; GCA treated with IFNγ: 9; GCA treated with
dexamethasone: 11.
Bold values indicate consistent opposite results achieved by blocking IFNγ with A6 or
by adding recombinant IFNγ.
*p<0.05.
Clone A6, anti-human IFNγ monoclonal antibody; GCA, giant cell arteritis; IgG1,
isotype-matched control immunoglobulin; ICAM, intracellular adhesion molecule; IFNγ,
recombinant interferon γ; MMP, matrix metalloproteinases; PDGF, platelet-derived
growth factor.
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Chemokine-rich supernatant of VSMC exposed to IFNγ
stimulated PBMC chemotaxis in Boyden chambers (ﬁgure 4C),
and this increase was abrogated by an antagonist of
CXCR3, chemokine receptor common to CCL9, CXCL10 and
CXCL11.
Effects of IFNγ neutralisation on inﬁltrating mononuclear
cells in cultured temporal arteries from patients with GCA
The above ﬁndings suggest an important role for IFNγ in the
initial recruitment of inﬂammatory cells in temporal arteries
from patients with GCA and the participation of VSMC, the
major component of normal arteries in this process. To conﬁrm
this hypothesis, normal temporal arteries were exposed to
recombinant IFNγ and induction of CXCL9, CXCL10 and
CXCL11 was conﬁrmed (ﬁgure 5A). Incubation of IFNγ-treated
normal arteries with PBMC from healthy donors resulted in
inﬁltration of the artery wall by CD68 macrophages, which
formed aggregates resembling giant cells (ﬁgure 5B). No
CD3-positive cells penetrated the artery walls.
We next exposed cultured temporal arteries from patients
with GCA to A6 and explored changes in the number of inﬁl-
trating T cells (CD3) and macrophages (CD68). Blocking IFNγ
did not decrease the number of T cells (data not shown) but
reduced the number of CD68-expressing cells and abrogated the
presence of giant cells (ﬁgures 5C, D).
DISCUSSION
In this study, the ﬁrst attempt to investigate the functional role
of IFNγ in GCA, blocking endogenous IFNγ with a neutralising
anti-IFNγ antibody, led to a signiﬁcant reduction of STAT-1 and
chemokine CXCL9, CXCL10 and CXCL11 expression in ex
vivo cultured GCA arteries. Moreover, neutralising IFNγ
resulted in decreased inﬁltration by CD68-expressing macro-
phages and reduced expression of TNFα along with a non-
signiﬁcant trend to decrease inﬂammatory molecules typical of a
proinﬂammatory (M1-like) phenotype (HLA-DRA and inducible
nitric oxide synthase).20 These molecules, previously known to
be expressed in GCA, are modulated by IFNγ in other
Figure 2 Changes in gene expression and protein secretion induced by blocking interferon γ (IFNγ) with A6 or adding additional IFNγ on cultured
giant cell arteritis (GCA) biopsies. (A) mRNA concentrations (relative units) of CXCL9, CXCL10, CXCL11 and STAT-1 in cultured control arteries
(negative biopsy) versus cultured GCA-involved arteries untreated or exposed to A6, human IgG1, or dexamethasone (Dexa) at the same
concentrations as in ﬁgure 1. Statistical comparisons was performed between histologically negative and GCA-involved arteries and between
IgG1-treated and A6-treated GCA involved arteries. *p<0.05; **p<0.005. Notice that the Y scale is different for each molecule. (B) mRNA
concentrations (relative units) of CXCL9, CXCL10, CXCL11 and STAT-1 in cultured histologically negative arteries (negative biopsy) versus
GCA-involved arteries untreated, or exposed to IFNγ or dexamethasone (Dexa) at the same concentrations as in ﬁgure 1 in a different set of
experiments. Statistical comparison was performed between histologically negative and GCA-involved arteries and between GCA arteries untreated
or treated with recombinant IFNγ. *p<0.05; **p<0.005. Notice that the Y scale is different for each molecule. (C) CXCL9, CXCL10 and CXCL11
concentrations (pg/mL) in the supernatants of cultured normal arteries and GCA-affected arteries untreated or exposed to A6, human IgG1, IFNγ or
Dexa at the same concentrations as in ﬁgure 1. Statistical comparison was performed between histologically negative and GCA-involved arteries and
between IgG1-treated and A6-treated GCA involved arteries. *p<0.05; **p<0.005.
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Figure 3 Effect of blocking the spontaneous interferon γ (IFNγ) production by co-cultured vascular smooth muscle cells (VSMCs) and peripheral
blood mononuclear cells (PBMCs) on chemokine expression and effect of adding IFNγ on chemokine expression by temporal artery-derived VSMC.
(A) VSMCs from normal temporal arteries were incubated alone or with PBMC (healthy donor) per well for 24 h. PBMCs were also cultured alone as
a control. Cells were cultured with (A6) (ﬁlled bars) or without (Ø) (empty bars) the anti-IFNγ mAb A6 (10 μg/mL). After co-culture, PBMCs
(adherent and non-adherent) were separated from VSMC. RNA was extracted from each individualized cell type: PBMC cultured alone, VSMC
cultured alone, co-cultured PBMC (adherent and non-adherent) and co-cultured VSMC, and mRNA levels of various chemokines was determined.
Notice that the Y scale is different for each molecule. The experiment was repeated three times with consistent results. *Signiﬁcant reduction by A6
p<0.05 (B) Cultured VSMCs obtained from histologically normal temporal arteries were exposed to increasing concentrations of recombinant
IFNγ(0-20-50-100 ng/mL) for 24 h and expression of transcription factors STAT-1 and STAT-3, chemokines and adhesion molecules intracellular
adhesion molecule (ICAM)-1 and vascular adhesion molecule (VCAM)-1 was assessed by real-time quantitative RT-PCR. All increases in expression of
chemokines, ICAM-1, STAT-1 and VCAM-1 were statistically signiﬁcant (p<0.05) compared to baseline. Increase in STAT-3 was signiﬁcant (p<0.05)
at the highest IFNγ concentration. (C) Spontaneous chemokine mRNA expression (relative units) by primary cultures of VSMC obtained from 11
normal arteries (empty boxes) or giant cell arteritis (GCA)-involved arteries (ﬁlled boxes). *p<0.05.
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settings.5 19 20 23 26 Treatment of GCA arteries with exogenous
IFNγ elicited opposite effects and tendencies, supporting the
speciﬁcity of these ﬁndings.
Blocking IFNγ in our system led to a highly selective inhib-
ition of ISRE-containing chemokine genes CXCL 9, 10 and 11.
Although IFNγ also induced ISRE-dependent CCL2 in isolated
VSMC, the effect of blocking IFNγ on CCL2 expression in
GCA arteries was not apparent probably due to the remarkable
constitutive expression of CCL2 in aged temporal arteries and
the presence of potential additional inducers.34 Since CXCL 9,
10 and 11 are powerful chemoattractants of mononuclear cells
and these are able to interact with ICAM-1 expressing microves-
sels in inﬂamed arteries, our ﬁndings support a relevant role for
IFNγ in the development and perpetuation of inﬂammatory
inﬁltrates.
Based on the potent known effects of IFNγ on macrophages,
and their predominance in GCA lesions, we expected that
blocking IFNγ would have higher impact in the expression of
downstream macrophage inﬂammatory products such as
HLA-DR, NOS-2 and monokines.20 In our model, IFNγ
Figure 4 Changes in vascular smooth muscle cell (VSMCs) adhesiveness and chemoattraction to peripheral blood mononuclear cells (PBMCs) upon
exposure to interferon γ (IFNγ). (A) PBMC adhesion to VSMC obtained from histologically normal temporal arteries and exposed to increasing
concentrations of IFNγ. VSMC cultured in 96-well plates were exposed to increasing concentrations of IFNγ (0–20–50–100 ng/mL) for 24 h. PBMCs
(75 000/well) were added and incubated for 1 h, washed and stained with crystal violet. Bars represent absorbance of solubilised dye in VSMC
incubated with PBMC after subtraction of absorbance obtained from VSMC alone. *p<0.05. In parallel conﬁrmatory experiments, VSMCs were
seeded in chamber slides (Nunc, Waltham, Massachusetts, USA), and VSMCs were immunostained with a mouse monoclonal anti-human alpha
smooth muscle actin antibody (ab54723, Abcam) (green). Nuclei were stained with DAPI (blue). The size of PBMC nuclei (indicated by arrows) are
smaller than those from VSMC and can be easily distinguished. (B) Expression of intracellular adhesion molecule (ICAM)-1 (green) and CD31 (red) in
temporal arteries from a patient with giant cell arteritis (GCA) exposed to IgG1 (10 μg/mL), A6 (10 μg/mL) or IFNγ (100 ng/mL)for 5 days. Nuclei
were stained with DAPI (blue). VSMCs (elongated cells) express ICAM -1, particularly in the vicinity of inﬁltrating mononuclear cells. Co-expression
of CD31 and ICAM-1 (merged, yellow) is observed on endothelial cells from adventitial vasa vasorum and neovessels. ICAM-1 expression is clearly
reduced by A6 antibody. (C) Chemotactic activity of PBMC to the supernatant of VSMC exposed to IFNγ. Supernatants from VSMC obtained from
histologically normal arteries incubated with increasing concentrations IFNγ (0–20–50 ng/mL) for 24 h were used to assess the induction of PBMC
chemotaxis in the presence or in the absence of the CXCR3 inhibitor 500486. Bars represent the number of cells/mL that migrated to the lower
chamber after 6 h incubation (mean±SD of three counts). *p<0.05 (increase in migration at any IFNγ concentration versus baseline). #p<0.05
(inhibition by CXCR3 antagonist).
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neutralisation slightly modiﬁed or did not modify at all a
number of relevant proinﬂammatory molecules that were,
indeed, suppressed by GC. This may be determined by con-
comitant activation of IFNγ-independent pathways. In this
regard, neutralisation of IFNγ did not substantially reduce
expression and activation of STAT-3, which appears to be highly
activated in normal arteries and in GCA lesions, in accordance
with the remarkable production of IL-6 in normal and inﬂamed
arteries.4–6 Concomitant activation of STAT-3 and nuclear
factor-κB may sustain expression of many inﬂammatory mole-
cules in spite of IFNγ blockade.35–37
Most of the studies investigating IFNγ proinﬂammatory func-
tions have explored its effects on macrophages and endothelial
cells.18 33 In vascular biology, the effects of IFNγ have been
Figure 5 Effect of interferon γ (IFNγ) on chemokine expression and macrophage inﬁltration of histologically normal temporal arteries and
reduction of macrophage inﬁltration in giant cell arteritis (GCA)-involved arteries following IFNγ blockade. (A) Histologically normal temporal arteries
(N=6) were cultured on Matrigel with or without IFNγ (100 ng/mL) for 5 days and chemokine mRNA expression was assessed (relative units) by
RT-PCR. (B) Histologically normal temporal arteries cultured in 24-well plates as above were incubated in medium alone or in medium containing
IFNγ (100 ng/mL) for 4 days and were subsequently exposed to PBMC from a healthy donor (0.25×106/well) for 5 days. Cryosections of the retrieved
arteries were processed for immunoﬂuorescence, sectioned and immunostained with an anti-CD68 mAb (red). Nuclei were stained with DAPI (blue).
(C) GCA affected temporal arteries were cultured in medium alone or in medium containing A6 antibody (10 μg/mL), control IgG1 (10 μg/mL) or
recombinant IFNγ (100 ng/mL) for 5 days, washed and processed for immunoﬂuorescence and immunostained with anti-CD68 mAb as in (B). Nuclei
were stained with DAPI (blue). (D) Cryosections of GCA-affected temporal arteries, cultured as in (C), were immunostained with an anti-CD68 mAb.
Notice reduction in immunostained CD68 cells and disappearance of giant cells (arrows) following anti-IFNγ or dexamethasone (Dexa) (0.5 μg/mL)
treatment. Graph shows number of CD68+ cells/ﬁeld (×100) in cultured GCA-involved temporal arteries untreated or exposed to A6, control IgG1 or
dexamethasone (Dexa). Twelve ﬁelds/condition were assessed. *p<0.05.
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essentially investigated in the setting of atherosclerosis and graft
vasculopathy.38 39 In these models, IFNγ is expressed in lesions
and production of IFNγ induced chemokines have been attribu-
ted to endothelial cells and inﬂammatory cells and only occa-
sionally related to myoﬁbroblasts.38 In VSMC, the effects of
IFNγ have been mainly related to vascular remodelling and
neointima formation.39 In recent years, it has become apparent
that VSMC may acquire a strong proinﬂammatory phenotype in
the appropriate context.40 41 Our ﬁndings indicate that, in
GCA, VSMC are also important targets for IFNγ, which renders
them active producers of chemokines and adhesion molecules,
especially ICAM-1. Consequently, VSMCs likely contribute to
the progression of inﬂammatory inﬁltrates through the medial
layer of the artery wall and to the development of full-blown
granulomatous lesions in GCA.
GC, the cornerstone of current GCA treatment, rapidly
downregulate the expression of a variety of inﬂammatory cyto-
kines (ie, IL-1β, TNFα, IL-6, IL-17), adhesion molecules (ie,
ICAM-1) and matrix metalloproteinases (ie, MMP-9).7 11 27 28
However, GC do not repress IFNγ transcription.35 Although
prolonged GC treatment eventually results in decreased IFNγ
expression by other mechanisms,11 42–44 acute GC effects on
IFNγ expression in GCA lesions are less dramatic than that
observed with other cytokines.7 27 35 This has led to the
hypothesis that incomplete suppression of IFNγ accounts for
GCA relapses during GC tapering or withdrawal,29 and IFNγ
has been considered a potential therapeutic target.29 35
However, our ﬁndings indicate that reducing STAT-1 expression
and activation by blocking IFNγ may not be sufﬁcient to abro-
gate inﬂammatory activity in full-blown GCA lesions, which
may require blockade of multiple pathways. However, interfer-
ing with IFNγ might be useful in preventing relapses, given the
relevant role of IFNγ in the recruitment of inﬂammatory cells
since the very early inﬂammatory stages.11 45
In considering IFNγ as a potential therapeutic target, it is
important to consider that IFNγ may have a protective role by
limiting tissue injury.16 46 Blocking IFNγ worsens, indeed, experi-
mental arthritis by promoting Th17 differentiation and exacerba-
tion of IL-17-mediated inﬂammatory responses.47 In addition, an
infectious trigger of GCA has been postulated, although no causa-
tive agents have been consistently identiﬁed.48 In this regard,
IFNγ-deﬁcient mice infected with murine herpesvirus HV68
develop necrotising large-vessel vasculitis, supporting the well-
known role of IFNγ in host defence against viruses but also sug-
gesting a role in limiting vascular injury.46 49 Moreover, in some
experimental settings, but not in others, IFNγ deﬁciency exacer-
bates aortic aneurysm development, which is one of the import-
ant delayed complications of GCA.50–56
Our study has several limitations. On the one hand, it
explores functional activities of IFNγ in a target organ isolated
from a functional immune system and variations in chemokine
and adhesion molecule expression could not result in effective
changes in leucocyte recruitment. It is likely that, in vivo, inhib-
ition of lymphocyte and monocyte recruitment and subsequent
macrophage activation would result in greater impact on the
generation of downstream inﬂammatory products. In addition,
as mentioned, the culture itself downregulates IFNγ expression,7
which may have minimised the effect of IFNγ neutralisation in
our model. GC treatment of some patients prior to the TAB
may also have inﬂuenced results.7
In spite of these limitations, our ﬁndings indicate an important
role for IFNγ in the recruitment and activation of macrophages,
which may sustain and amplify subsequent waves of proinﬂamma-
tory cascades in GCA. Moreover, our ﬁndings support the
suitability of the temporal artery culture model to test functional
activities not only of pharmacological agents or chemicals but
also of complex molecules such as biological agents.
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